IL173382A0 - Amino acid prodrugs - Google Patents

Amino acid prodrugs

Info

Publication number
IL173382A0
IL173382A0 IL173382A IL17338206A IL173382A0 IL 173382 A0 IL173382 A0 IL 173382A0 IL 173382 A IL173382 A IL 173382A IL 17338206 A IL17338206 A IL 17338206A IL 173382 A0 IL173382 A0 IL 173382A0
Authority
IL
Israel
Prior art keywords
amino acid
acid prodrugs
prodrugs
amino
acid
Prior art date
Application number
IL173382A
Original Assignee
Signature R & D Holdings Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Signature R & D Holdings Llc filed Critical Signature R & D Holdings Llc
Publication of IL173382A0 publication Critical patent/IL173382A0/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K5/00Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06Dipeptides
    • C07K5/06191Dipeptides containing heteroatoms different from O, S, or N
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/02Peptides of undefined number of amino acids; Derivatives thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/04Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/12Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
    • A61K38/13Cyclosporins
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/542Carboxylic acids, e.g. a fatty acid or an amino acid
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K7/00Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/64Cyclic peptides containing only normal peptide links
    • C07K7/645Cyclosporins; Related peptides
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02ATECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Diabetes (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Neurosurgery (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Neurology (AREA)
  • Pain & Pain Management (AREA)
  • Cardiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
IL173382A 2003-07-29 2006-01-26 Amino acid prodrugs IL173382A0 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US49133103P 2003-07-29 2003-07-29
PCT/US2004/024901 WO2005046575A2 (en) 2003-07-29 2004-07-29 Amino acid prodrugs

Publications (1)

Publication Number Publication Date
IL173382A0 true IL173382A0 (en) 2006-06-11

Family

ID=34590076

Family Applications (1)

Application Number Title Priority Date Filing Date
IL173382A IL173382A0 (en) 2003-07-29 2006-01-26 Amino acid prodrugs

Country Status (11)

Country Link
EP (1) EP1660017A4 (en)
JP (2) JP2007510621A (en)
KR (3) KR20060073584A (en)
CN (1) CN101123878A (en)
AU (1) AU2004289174B2 (en)
CA (1) CA2534342C (en)
IL (1) IL173382A0 (en)
NZ (3) NZ601772A (en)
SG (2) SG145693A1 (en)
WO (1) WO2005046575A2 (en)
ZA (1) ZA200600660B (en)

Families Citing this family (107)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20060073584A (en) * 2003-07-29 2006-06-28 시그너쳐 알 앤드 디 홀딩스, 엘엘씨 Amino acid prodrugs
US8173840B2 (en) 2003-07-29 2012-05-08 Signature R&D Holdings, Llc Compounds with high therapeutic index
US7589233B2 (en) 2003-07-29 2009-09-15 Signature R&D Holdings, Llc L-Threonine derivatives of high therapeutic index
ZA200605383B (en) 2003-12-29 2008-06-25 Sepracor Inc Pyrrole and pyrazole daao inhibitors
KR101142583B1 (en) * 2004-01-07 2012-05-11 세이가가쿠 고교 가부시키가이샤 Hyaluronic acid derivative and drug containing the same
WO2006017351A1 (en) 2004-07-12 2006-02-16 Xenoport, Inc. Prodrugs of propofol, compositions and uses thereof
EP1964578A3 (en) * 2005-05-05 2008-11-05 Chroma Therapeutics Limited Alpha aminoacid ester-drug conjugates hydrolysable by carboxylesterase
EP2789341A3 (en) * 2005-11-11 2015-01-14 V. Ravi Chandran O-acetylated amino acids as anti-platelet agents and nutritional supplements
WO2007081542A2 (en) 2006-01-06 2007-07-19 Sepracor Inc. Tetralone-based monoamine reuptake inhibitors
RU2430913C2 (en) 2006-01-06 2011-10-10 Сепракор Инк. Cycloalkylamines as monoamine reuptake inhibitors
US7696166B2 (en) 2006-03-28 2010-04-13 Albany Molecular Research, Inc. Use of cyclosporin alkyne/alkene analogues for preventing or treating viral-induced disorders
US7696165B2 (en) 2006-03-28 2010-04-13 Albany Molecular Research, Inc. Use of cyclosporin alkyne analogues for preventing or treating viral-induced disorders
DK2013835T3 (en) 2006-03-31 2015-12-14 Sunovion Pharmaceuticals Inc Preparation of chiral amides and AMINES
US7884124B2 (en) 2006-06-30 2011-02-08 Sepracor Inc. Fluoro-substituted inhibitors of D-amino acid oxidase
CA2938241A1 (en) 2006-07-06 2008-01-10 Cytovia, Inc. Substituted 4-aryl-chromene as activator of caspases and inducer of apoptosis and as antivascular agent and the use thereof
CN1907954B (en) * 2006-08-16 2011-11-23 重庆医科大学医药研究所 Water-soluble derivative of anesthetic 2,6-diisopropyl phenol and preparation method thereof
CA2668070A1 (en) 2006-10-30 2008-05-08 Chroma Therapeutics Ltd. Hydroxamates as inhibitors of histone deacetylase
US7902252B2 (en) 2007-01-18 2011-03-08 Sepracor, Inc. Inhibitors of D-amino acid oxidase
BRPI0811639A2 (en) 2007-05-31 2014-09-30 Sepracor Inc FENY CYCLOAKILAMINES REPLACED AS MONOAMINE RECAPTATION INHIBITORS
US20090054450A1 (en) * 2007-06-19 2009-02-26 Ironwood Pharmaceuticals, Inc. Compositions and methods of use for treating or preventing lipid related disorders
US8778953B2 (en) 2008-02-29 2014-07-15 Chroma Therapeutics Ltd. Inhibitors of P38 map kinase
TWI503101B (en) * 2008-12-15 2015-10-11 Proteus Digital Health Inc Body-associated receiver and method
AU2009327322A1 (en) 2008-12-19 2011-06-30 Pinnacle Pharmaceuticals, Inc. Phenazopyridine compounds
CN102596896A (en) * 2009-06-24 2012-07-18 夏尔有限责任公司 Mexiletine amino acid and peptide prodrugs and uses thereof
WO2011060049A2 (en) 2009-11-12 2011-05-19 The Regents Of The University Of Michigan Spiro-oxindole mdm2 antagonists
MX2012008922A (en) 2010-02-01 2012-10-05 Proteus Digital Health Inc Data gathering system.
CN101906039B (en) * 2010-06-23 2013-05-08 四川大学华西医院 Hydroxyl acid ester compound of substituted phenol, preparation method and application in drug
MX2010011006A (en) * 2010-10-06 2012-04-18 Senosiain S A De C V Lab New salt of a pyrimidin derivative.
UA109464C2 (en) 2010-11-12 2015-08-25 Дзе Ріджентс Оф Дзе Юніверсіті Оф Мічіган Spiro-oxindoles as mdm2 antagonists
US20120196933A1 (en) * 2010-12-23 2012-08-02 Richard Franklin Mexiletine prodrugs
CA2835422C (en) 2011-05-11 2016-10-11 The Regents Of The University Of Michigan Spiro-oxindole mdm2 antagonists
FR2976944A1 (en) 2011-06-21 2012-12-28 Centre Nat Rech Scient PEPTIDE PRODUCTS
WO2015112603A1 (en) 2014-01-21 2015-07-30 Proteus Digital Health, Inc. Masticable ingestible product and communication system therefor
WO2014037832A2 (en) 2012-09-06 2014-03-13 Mahesh Kandula Compositions and methods for the treatment of epilepsy and neurological diseases
EP2773378B1 (en) 2011-10-31 2016-08-10 Larsen, Claus Selch Prodrugs of non-steroid anti-inflammatory agents (nsaids)
ES2802251T3 (en) 2012-01-06 2021-01-18 Novartis Ag Heterocyclic compounds and methods for their use
WO2013167985A1 (en) 2012-05-07 2013-11-14 Mahesh Kandula Compositions and methods for the treatment of neurological disorders
CN104379589A (en) * 2012-05-07 2015-02-25 塞利克斯比奥私人有限公司 Prodrugs of anti-platelet agents
US9399634B2 (en) 2012-05-07 2016-07-26 Cellix Bio Private Limited Compositions and methods for the treatment of depression
EP2847158A4 (en) 2012-05-07 2015-12-30 Cellix Bio Private Ltd Compositions and methods for treatment of neuromuscular disorders and neurodegenerative disorders
US9309233B2 (en) 2012-05-08 2016-04-12 Cellix Bio Private Limited Compositions and methods for the treatment of blood clotting disorders
US9403826B2 (en) 2012-05-08 2016-08-02 Cellix Bio Private Limited Compositions and methods for the treatment of inflammatory disorders
US9266823B2 (en) 2012-05-08 2016-02-23 Cellix Bio Private Limited Compositions and methods for the treatment of parkinson's disease
US9434704B2 (en) 2012-05-08 2016-09-06 Cellix Bio Private Limited Compositions and methods for the treatment of neurological degenerative disorders
WO2013167991A1 (en) 2012-05-08 2013-11-14 Mahesh Kandula Compositions and methods for the treatment of metabolic disorders
WO2013168000A1 (en) 2012-05-10 2013-11-14 Mahesh Kandula Compositions and methods for the treatment of severe pain
US9315478B2 (en) 2012-05-10 2016-04-19 Cellix Bio Private Limited Compositions and methods for the treatment of metabolic syndrome
WO2013168012A1 (en) 2012-05-10 2013-11-14 Mahesh Kandula Compositions and methods for the treatment of respiratory disorders
WO2013168015A1 (en) 2012-05-10 2013-11-14 Mahesh Kandula Compositions and methods for the treatment of asthma and allergy
WO2013168004A2 (en) 2012-05-10 2013-11-14 Mahesh Kandula Compositions and methods for the treatment of fibromyalgia pain
WO2013168001A1 (en) 2012-05-10 2013-11-14 Mahesh Kandula Compositions and methods for the treatment of moderate to severe pain
US9499527B2 (en) 2012-05-10 2016-11-22 Cellix Bio Private Limited Compositions and methods for the treatment of familial amyloid polyneuropathy
US9403857B2 (en) 2012-05-10 2016-08-02 Cellix Bio Private Limited Compositions and methods for the treatment of metabolic syndrome
WO2013167999A2 (en) 2012-05-10 2013-11-14 Mahesh Kandula Compositions and methods for the treatment of neurologic diseases
US9273061B2 (en) 2012-05-10 2016-03-01 Cellix Bio Private Limited Compositions and methods for the treatment of chronic pain
WO2013168005A2 (en) 2012-05-10 2013-11-14 Mahesh Kandula Compositions and methods for the treatment of restless leg syndrome and fibromyalgia
US9233161B2 (en) 2012-05-10 2016-01-12 Cellix Bio Private Limited Compositions and methods for the treatment of neurological conditions
US9499526B2 (en) 2012-05-10 2016-11-22 Cellix Bio Private Limited Compositions and methods for the treatment of neurologic diseases
CA3189252A1 (en) 2012-05-16 2013-11-21 Techfields Pharma Co., Ltd. High penetration prodrug compositions and pharmaceutical composition thereof for treatment of pulmonary conditions
CA2873104A1 (en) 2012-05-23 2013-11-28 Cellixbio Private Limited Compositions and methods for the treatment of mucositis
WO2013175347A2 (en) 2012-05-23 2013-11-28 Mahesh Kandula Compositions and methods for the treatment of respiratory disorders
CN104603097A (en) 2012-05-23 2015-05-06 塞利克斯比奥私人有限公司 Compositions and methods for the treatment of multiple sclerosis
US9434729B2 (en) 2012-05-23 2016-09-06 Cellix Bio Private Limited Compositions and methods for the treatment of periodontitis and rheumatoid arthritis
JP6202287B2 (en) 2012-05-23 2017-09-27 セリックスビオ プライヴェート リミテッド Compositions and methods for the treatment of inflammatory bowel disease
US9492409B2 (en) 2012-05-23 2016-11-15 Cellix Bio Private Limited Compositions and methods for the treatment of local pain
US9108942B1 (en) 2014-11-05 2015-08-18 Mahesh Kandula Compositions and methods for the treatment of moderate to severe pain
US9187427B2 (en) 2012-08-03 2015-11-17 Cellix Bio Private Limited N-substituted nicotinamide compounds and compositions for the treatment migraine and neurologic diseases
TWI601725B (en) * 2012-08-27 2017-10-11 加拓科學公司 Substituted azaindole compounds, salts, pharmaceutical compositions thereof and methods of use
US9624168B2 (en) 2012-09-06 2017-04-18 Cellix Bio Private Limited Compositions and methods for the treatment inflammation and lipid disorders
WO2014037834A2 (en) 2012-09-08 2014-03-13 Mahesh Kandula Compositions and methods for the treatment of inflammation and lipid disorders
CN102924398B (en) * 2012-11-22 2015-11-18 安徽贝克生物制药有限公司 For removing the method for the corresponding isomer of efavirenz
CN103880754A (en) * 2012-12-21 2014-06-25 西藏海思科药业集团股份有限公司 Alkaline amino acid ester salt of propofol
WO2014151929A1 (en) 2013-03-15 2014-09-25 Proteus Digital Health, Inc. Personal authentication apparatus system and method
CN103263405B (en) * 2013-05-08 2015-04-22 南京医科大学 Medicinal composition for treating diabetes, and its application
US9333187B1 (en) 2013-05-15 2016-05-10 Cellix Bio Private Limited Compositions and methods for the treatment of inflammatory bowel disease
WO2014195961A1 (en) 2013-06-04 2014-12-11 Mahesh Kandula Compositions and methods for the treatment of diabetes and pre-diabetes
CN103360240B (en) * 2013-07-23 2015-03-11 西安新通药物研究有限公司 Preparation method of high purity fenofibric acid
MX356850B (en) 2013-09-20 2018-06-15 Proteus Digital Health Inc Methods, devices and systems for receiving and decoding a signal in the presence of noise using slices and warping.
US10084880B2 (en) 2013-11-04 2018-09-25 Proteus Digital Health, Inc. Social media networking based on physiologic information
WO2016110865A1 (en) 2015-01-06 2016-07-14 Cellix Bio Private Limited Compositions and methods for the treatment of inflammation and pain
US9096537B1 (en) 2014-12-31 2015-08-04 Mahesh Kandula Compositions and methods for the treatment of mucositis
SI3701971T1 (en) 2014-03-14 2023-01-31 Biomolecular Holdings LLC, Compounds useful in preparing hybrid immunoglobulin containing non-peptidyl linkage
CN103951557B (en) * 2014-04-22 2016-06-08 徐州工业职业技术学院 A kind of method with inorganic base for catalyst preparing fenofibrate
US10471118B2 (en) 2014-05-30 2019-11-12 Case Western Reserve University Retinylamine derivitives for treatment of ocular disorders
SG11201706952VA (en) 2014-09-26 2017-10-30 Cellix Bio Private Ltd Compositions and methods for the treatment of epilepsy and neurological disorders
CN107207403A (en) 2014-09-29 2017-09-26 塞尔利克斯生物私人有限公司 Composition and method for treating multiple sclerosis
CN107108535B (en) 2014-10-27 2020-04-28 塞尔利克斯生物私人有限公司 Three-component salts of monomethyl fumarate with piperazine or ethylenediamine for the treatment of multiple sclerosis
US9284287B1 (en) 2014-11-05 2016-03-15 Cellix Bio Private Limited Compositions and methods for the suppression of carbonic anhydrase activity
US9175008B1 (en) 2014-11-05 2015-11-03 Cellix Bio Private Limited Prodrugs of anti-platelet agents
US9290486B1 (en) 2014-11-05 2016-03-22 Cellix Bio Private Limited Compositions and methods for the treatment of epilepsy
US10208014B2 (en) 2014-11-05 2019-02-19 Cellix Bio Private Limited Compositions and methods for the treatment of neurological disorders
US9321716B1 (en) 2014-11-05 2016-04-26 Cellix Bio Private Limited Compositions and methods for the treatment of metabolic syndrome
US9173877B1 (en) 2014-11-05 2015-11-03 Cellix Bio Private Limited Compositions and methods for the treatment of local pain
US9150557B1 (en) 2014-11-05 2015-10-06 Cellix Bio Private Limited Compositions and methods for the treatment of hyperglycemia
US9932294B2 (en) 2014-12-01 2018-04-03 Cellix Bio Private Limited Compositions and methods for the treatment of multiple sclerosis
US9206111B1 (en) 2014-12-17 2015-12-08 Cellix Bio Private Limited Compositions and methods for the treatment of neurological diseases
CN104628554A (en) * 2015-02-09 2015-05-20 徐州工程学院 Fenofibric acid crystal form and preparation method thereof
CN106146444A (en) * 2015-04-03 2016-11-23 米文君 A kind of new compound and application thereof
CN105037180B (en) * 2015-04-19 2017-10-10 安徽省逸欣铭医药科技有限公司 Central analgesia noval chemical compound, the Preparation method and use of a kind of double action
BR112018068886A2 (en) * 2016-03-18 2019-01-22 Caregen Co Ltd finasteride conjugate with peptide
WO2017193562A1 (en) * 2016-05-10 2017-11-16 浙江海正药业股份有限公司 Water soluble rapamycin derivative
CN106316921B (en) * 2016-08-19 2019-03-29 河南东泰制药有限公司 A kind of preparation method of acemetacin
CN108948140B (en) * 2017-05-18 2021-10-26 首都医科大学 warfarin-4-O-acetyl-Arg-AA eleven compounds, and synthesis, activity and application thereof
CN108948139B (en) * 2017-05-18 2021-10-26 首都医科大学 warfarin-4-O-acetyl-Arg-AA compounds, their synthesis, activity and use
UY38072A (en) 2018-02-07 2019-10-01 Novartis Ag COMPOSITIONS DERIVED FROM BUTANOIC ESTER SUBSTITUTED WITH BISPHENYL AS INHIBITORS OF NEP, COMPOSITIONS AND COMBINATIONS OF THE SAME
CN108299219A (en) * 2018-02-11 2018-07-20 中国农业大学 O- is acylated serine derivative and the preparation method and application thereof
DK3678705T3 (en) 2018-09-14 2023-06-26 Enlitisa Shanghai Pharmaceutical Co Ltd Conjugates of montelukast and peptides

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4650803A (en) * 1985-12-06 1987-03-17 University Of Kansas Prodrugs of rapamycin
US5411947A (en) * 1989-06-28 1995-05-02 Vestar, Inc. Method of converting a drug to an orally available form by covalently bonding a lipid to the drug
EP0586512A1 (en) * 1991-05-31 1994-03-16 Pfizer Inc. Use of rapamycin prodrugs as immunosuppressant agents
US5972379A (en) * 1995-02-14 1999-10-26 Sequus Pharmaceuticals, Inc. Liposome composition and method for administering a quinolone
JPH1143467A (en) * 1997-05-14 1999-02-16 Ikeda Mohandou:Kk Fatty acid glyceride derivative and glyceride derivative, and their production
IT1294205B1 (en) * 1997-07-23 1999-03-24 Farmigea Spa PROCEDURE FOR THE SOLUBILIZATION IN WATER AND IN AQUEOUS VEHICLES OF PHARMACOLOGICALLY ACTIVE SUBSTANCES
CA2418479C (en) * 2000-08-18 2007-12-18 The Board Of Trustees Of The University Of Illinois Prodrugs of betulinic acid derivatives for the treatment of cancer
US20020160988A1 (en) * 2001-02-20 2002-10-31 Israel Institute For Biological Research Compounds co-inducing cholinergic up-regulation and inflammation down-regulation and uses thereof
US7045543B2 (en) * 2001-11-05 2006-05-16 Enzrel Inc. Covalent conjugates of biologically-active compounds with amino acids and amino acid derivatives for targeting to physiologically-protected sites
ATE396731T1 (en) * 2003-03-25 2008-06-15 Vertex Pharma THIAZOLES FOR USE AS INHIBITORS OF PROTEIN KINASES
KR20060073584A (en) * 2003-07-29 2006-06-28 시그너쳐 알 앤드 디 홀딩스, 엘엘씨 Amino acid prodrugs

Also Published As

Publication number Publication date
EP1660017A2 (en) 2006-05-31
JP2007510621A (en) 2007-04-26
AU2004289174A1 (en) 2005-05-26
WO2005046575A3 (en) 2007-10-04
KR20120116991A (en) 2012-10-23
CA2534342A1 (en) 2005-05-26
AU2004289174B2 (en) 2011-05-19
NZ601772A (en) 2012-10-26
SG145693A1 (en) 2008-09-29
EP1660017A4 (en) 2011-03-09
CA2534342C (en) 2016-05-10
ZA200600660B (en) 2007-04-25
WO2005046575A2 (en) 2005-05-26
AU2004289174A2 (en) 2005-05-26
JP2013035863A (en) 2013-02-21
SG178721A1 (en) 2012-03-29
KR20060073584A (en) 2006-06-28
KR20130081319A (en) 2013-07-16
NZ601780A (en) 2012-10-26
CN101123878A (en) 2008-02-13
NZ545570A (en) 2012-07-27

Similar Documents

Publication Publication Date Title
IL173382A0 (en) Amino acid prodrugs
GB0306907D0 (en) Boireductively-activated prodrugs
GB2409010B (en) Quick connector
EP1698821A4 (en) Quick connector
HK1106339A1 (en) Connector
HK1093724A1 (en) Biaryloxymethylarene-carboxylic acids
EP1710872A4 (en) Connector
HK1066153A1 (en) Buckle
GB0310593D0 (en) Peptidic prodrugs
EP1683534A4 (en) Connector
GB0326555D0 (en) Connector
TW565037U (en) Connector
EP1585750A4 (en) Narcistatin prodrugs
EP1683533A4 (en) Connector
PL377766A1 (en) Novel anticonvulsant derivative salts
GB2413715B (en) Connector
GB2413714B (en) Connector
GB0420607D0 (en) Amino acid
GB2409939B (en) Connector
GB2406366B (en) Connector
GB2404712B (en) Connector
GB0306394D0 (en) Carnitine retention
TW568434U (en) Connector
GB0314996D0 (en) Prodrugs
GB0425900D0 (en) Novel pyrrolopyridine-2-carboxylic acid amide